AIM: The study aimed to test simultaneously our understanding of the effects of bupropion sustained-release (SR) treatment on putative mediators and our understanding of determinants of post-quit abstinence, including withdrawal distress, cigarette craving, positive affect and subjective reactions to cigarettes smoked during a lapse. The specificity of bupropion SR effects was also tested in exploratory analyses. DESIGN: Data from a randomized, placebo-controlled clinical trial of bupropion SR were submitted to mediation analyses. SETTING: Center for Tobacco Research and Intervention, Madison, WI, USA. PARTICIPANTS: A total of 403 adult, daily smokers without contraindications to bupropion SR use. INTERVENTION: Participants were assigned randomly to receive a 9-week course of bupropion SR or placebo pill and to receive eight brief individual counseling sessions or no counseling. MEASUREMENTS: Ecological momentary assessment ratings of smoking behavior and putative mediators were collected pre- and post-quit. FINDINGS: Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette, but provided partial support for mediation by cigarette craving reduction and enhanced positive affect. Bupropion SR effects on point-prevalence abstinence at 1 month post-quit were also mediated partially by enhanced motivation to quit and self-efficacy. CONCLUSIONS: Results provided some support for models of bupropion SR treatment and relapse and suggested that motivational processes may partially account for bupropion SR efficacy.
RCT Entities:
AIM: The study aimed to test simultaneously our understanding of the effects of bupropion sustained-release (SR) treatment on putative mediators and our understanding of determinants of post-quit abstinence, including withdrawal distress, cigarette craving, positive affect and subjective reactions to cigarettes smoked during a lapse. The specificity of bupropion SR effects was also tested in exploratory analyses. DESIGN: Data from a randomized, placebo-controlled clinical trial of bupropion SR were submitted to mediation analyses. SETTING: Center for Tobacco Research and Intervention, Madison, WI, USA. PARTICIPANTS: A total of 403 adult, daily smokers without contraindications to bupropion SR use. INTERVENTION: Participants were assigned randomly to receive a 9-week course of bupropion SR or placebo pill and to receive eight brief individual counseling sessions or no counseling. MEASUREMENTS: Ecological momentary assessment ratings of smoking behavior and putative mediators were collected pre- and post-quit. FINDINGS: Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette, but provided partial support for mediation by cigarette craving reduction and enhanced positive affect. Bupropion SR effects on point-prevalence abstinence at 1 month post-quit were also mediated partially by enhanced motivation to quit and self-efficacy. CONCLUSIONS: Results provided some support for models of bupropion SR treatment and relapse and suggested that motivational processes may partially account for bupropion SR efficacy.
Authors: J K Ockene; K M Emmons; R J Mermelstein; K A Perkins; D S Bonollo; C C Voorhees; J F Hollis Journal: Health Psychol Date: 2000-01 Impact factor: 4.267
Authors: S Shiffman; M H Balabanis; J A Paty; J Engberg; C J Gwaltney; K S Liu; M Gnys; M Hickcox; S M Paton Journal: Health Psychol Date: 2000-07 Impact factor: 4.267
Authors: D Tashkin; R Kanner; W Bailey; S Buist; P Anderson; M Nides; D Gonzales; G Dozier; M K Patel; B Jamerson Journal: Lancet Date: 2001-05-19 Impact factor: 79.321
Authors: S Shiffman; J A Johnston; M Khayrallah; C A Elash; C J Gwaltney; J A Paty; M Gnys; G Evoniuk; J DeVeaugh-Geiss Journal: Psychopharmacology (Berl) Date: 2000-01 Impact factor: 4.530
Authors: Danielle E McCarthy; Thomas M Piasecki; Daniel L Lawrence; Douglas E Jorenby; Saul Shiffman; Michael C Fiore; Timothy B Baker Journal: Nicotine Tob Res Date: 2008-04 Impact factor: 4.244
Authors: Robert A Schnoll; Leonard Epstein; Janet Audrain; Raymond Niaura; Larry Hawk; Peter G Shields; Caryn Lerman; E Paul Wileyto Journal: J Subst Abuse Treat Date: 2007-06-27
Authors: Timothy B Baker; Robin Mermelstein; Linda M Collins; Megan E Piper; Douglas E Jorenby; Stevens S Smith; Bruce A Christiansen; Tanya R Schlam; Jessica W Cook; Michael C Fiore Journal: Ann Behav Med Date: 2011-04
Authors: Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern Journal: JAMA Psychiatry Date: 2014-07-01 Impact factor: 21.596
Authors: Yessenia Castro; Darla E Kendzor; Michael S Businelle; Carlos A Mazas; Ludmila Cofta-Woerpel; Paul M Cinciripini; David W Wetter Journal: Nicotine Tob Res Date: 2011-03-31 Impact factor: 4.244